Inhaled receptor antagonist reduces adverse chest symptoms from sumatriptan in models, suggesting a new treatment strategy.
Inhalation of a 5-HT1B/1D receptor antagonist effectively prevented sumatriptan-induced sensitization of CSLV afferents without diminishing sumatriptan's antimigraine efficacy. Our findings suggest that inhaled 5-HT1B/1D antagonists may offer a promising strategy to prevent or treat sumatriptan-induced adverse chest symptoms.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: